Cargando…
Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior
BACKGROUND: Refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. Approximately 15% of patients with major depressive disorder are refractory to currently available treatments. We hypothesized metabolic abnormalities contributing to treatment refr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520591/ https://www.ncbi.nlm.nih.gov/pubmed/36330595 http://dx.doi.org/10.1017/S0033291722003233 |
_version_ | 1785109954418442240 |
---|---|
author | Pan, Lisa A. Segreti, Anna Maria Wrobleski, Joseph Shaw, Annie Hyland, Keith Hughes, Marion Finegold, David N. Naviaux, Robert K. Brent, David A. Vockley, Jerry Peters, David G. |
author_facet | Pan, Lisa A. Segreti, Anna Maria Wrobleski, Joseph Shaw, Annie Hyland, Keith Hughes, Marion Finegold, David N. Naviaux, Robert K. Brent, David A. Vockley, Jerry Peters, David G. |
author_sort | Pan, Lisa A. |
collection | PubMed |
description | BACKGROUND: Refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. Approximately 15% of patients with major depressive disorder are refractory to currently available treatments. We hypothesized metabolic abnormalities contributing to treatment refractory depression are associated with distinct findings identifiable in the cerebrospinal fluid (CSF). Our hypothesis was confirmed by a previous small case-controlled study. Here we present a second, larger replication study. METHODS: We conducted a case-controlled, targeted, metabolomic evaluation of 141 adolescent and adult patients with well-characterized history of depression refractory to three maximum-dose, adequate-duration medication treatments, and 36 healthy controls. Plasma, urine, and CSF metabolic profiling were performed by coupled gas chromatography/mass spectrometry, and high-performance liquid chromatography, electrospray ionization, tandem mass spectrometry. RESULTS: Abnormalities were identified in 67 of 141 treatment refractory depression participants. The CSF abnormalities included: low cerebral folate (n = 20), low tetrahydrobiopterin intermediates (n = 11), and borderline low-tetrahydrobiopterin intermediates (n = 20). Serum abnormalities included abnormal acylcarnitine profile (n = 12) and abnormal serum amino acids (n = 20). Eighteen patients presented with two or more abnormal metabolic findings. Sixteen patients with cerebral folate deficiency and seven with low tetrahydrobiopterin intermediates in CSF showed improvement in depression symptom inventories after treatment with folinic acid and sapropterin, respectively. No healthy controls had a metabolite abnormality. CONCLUSIONS: Examination of metabolic disorders in treatment refractory depression identified an unexpectedly large proportion of patients with potentially treatable abnormalities. The etiology of these abnormalities and their potential roles in pathogenesis remain to be determined. |
format | Online Article Text |
id | pubmed-10520591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105205912023-09-27 Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior Pan, Lisa A. Segreti, Anna Maria Wrobleski, Joseph Shaw, Annie Hyland, Keith Hughes, Marion Finegold, David N. Naviaux, Robert K. Brent, David A. Vockley, Jerry Peters, David G. Psychol Med Original Article BACKGROUND: Refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. Approximately 15% of patients with major depressive disorder are refractory to currently available treatments. We hypothesized metabolic abnormalities contributing to treatment refractory depression are associated with distinct findings identifiable in the cerebrospinal fluid (CSF). Our hypothesis was confirmed by a previous small case-controlled study. Here we present a second, larger replication study. METHODS: We conducted a case-controlled, targeted, metabolomic evaluation of 141 adolescent and adult patients with well-characterized history of depression refractory to three maximum-dose, adequate-duration medication treatments, and 36 healthy controls. Plasma, urine, and CSF metabolic profiling were performed by coupled gas chromatography/mass spectrometry, and high-performance liquid chromatography, electrospray ionization, tandem mass spectrometry. RESULTS: Abnormalities were identified in 67 of 141 treatment refractory depression participants. The CSF abnormalities included: low cerebral folate (n = 20), low tetrahydrobiopterin intermediates (n = 11), and borderline low-tetrahydrobiopterin intermediates (n = 20). Serum abnormalities included abnormal acylcarnitine profile (n = 12) and abnormal serum amino acids (n = 20). Eighteen patients presented with two or more abnormal metabolic findings. Sixteen patients with cerebral folate deficiency and seven with low tetrahydrobiopterin intermediates in CSF showed improvement in depression symptom inventories after treatment with folinic acid and sapropterin, respectively. No healthy controls had a metabolite abnormality. CONCLUSIONS: Examination of metabolic disorders in treatment refractory depression identified an unexpectedly large proportion of patients with potentially treatable abnormalities. The etiology of these abnormalities and their potential roles in pathogenesis remain to be determined. Cambridge University Press 2023-10 2022-11-04 /pmc/articles/PMC10520591/ /pubmed/36330595 http://dx.doi.org/10.1017/S0033291722003233 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. |
spellingShingle | Original Article Pan, Lisa A. Segreti, Anna Maria Wrobleski, Joseph Shaw, Annie Hyland, Keith Hughes, Marion Finegold, David N. Naviaux, Robert K. Brent, David A. Vockley, Jerry Peters, David G. Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior |
title | Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior |
title_full | Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior |
title_fullStr | Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior |
title_full_unstemmed | Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior |
title_short | Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior |
title_sort | metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520591/ https://www.ncbi.nlm.nih.gov/pubmed/36330595 http://dx.doi.org/10.1017/S0033291722003233 |
work_keys_str_mv | AT panlisaa metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior AT segretiannamaria metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior AT wrobleskijoseph metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior AT shawannie metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior AT hylandkeith metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior AT hughesmarion metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior AT finegolddavidn metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior AT naviauxrobertk metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior AT brentdavida metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior AT vockleyjerry metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior AT petersdavidg metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior |